How GLP-1s Are Affecting Your Patients’ Oral Health

The new high-risk patient is already in your chair. She doesn’t look like anyone we were trained to catch.

Part 1 of a four-part series on GLP-1 medications and the mouth. Written for dental professionals.

Before we start: I am a dental hygienist (RDH, MPH) and a functional nutritionist. I am not a physician, and I do not prescribe. This is educational content, not medical advice, and nothing here should prompt anyone to start, stop, or change a prescribed medication — that conversation belongs to the patient and their prescriber. I’ved partnered with GC America on this series; therefore I have included links I do NOT receive commission on any purchase. 

Somewhere today, in an operatory a lot like yours, a clinician is going to look at four new lesions in a mouth that was clean a year ago, and tell the woman sitting in the chair that she needs to brush better.

 The RDH may ask about her snacking, or suggest she’s been slipping on the flossing, or gently wonder whether stress has gotten the better of her routine.

She will nod. She will apologize. She will feel a very specific kind of shame—the shame of a person who has been working harder on her health than she has in twenty years and is being told, by someone in a white coat, that she is still somehow not doing enough.

And she will walk out of that operatory with the actual cause of her disease completely unaddressed, because nobody in the room asked the only question that mattered.

Not what you are doing wrong. She isn’t doing anything wrong.

What did you start taking?

That is the question we are not asking, and it is costing our patients their teeth.

Our model of a high-risk patient has quietly expired

For most of my career, the high-caries-risk adult announced themselves.

The uncontrolled diabetic. The head-and-neck radiation patient. The Sjögren’s patient. The eighty-year-old on nine medications, four of them anticholinergic. We learned to spot them from across the room. We flagged them, tightened their intervals, adjusted their homecare. The system worked because the risk was legible. It looked like risk.

I have been lecturing on diabetes and the oral-systemic connection since 2020, and I will be honest with you: I thought I had this patient mapped. I thought I could see metabolic disease coming before it sat down.

I could not have been more wrong, because the highest-risk patient in my schedule now walks in looking like a success story.

She is down forty pounds. Her A1c is the best it has been in a decade. Her blood pressure is down, her energy is up, her physician is thrilled, and she is genuinely, visibly proud of herself — and she should be. She has done something extraordinarily hard, and it is working.

She is also sitting in front of me in active dysbiosis. High caries risk. Bleeding on probing in tissue that was tight and quiet at her last visit. Enamel going faintly translucent at the incisal edges, like sea glass.

Every visual cue we are trained to read is telling us this patient is fine. And every one of them is wrong.

That is what makes her so dangerous to miss. Her risk does not look like risk. It looks like health.

This is not a niche patient anymore

I want to put a number on this, because I think most of us are still filing GLP-1s under “trend” rather than “population.”

Roughly one in five American adults now says they have taken a GLP-1 medication, and about one in eight is taking one right now, according to KFF’s health tracking data.

Run that against your schedule. If you see eight patients in a day, one of them is on a GLP-1 today. If your practice sees a hundred patients a week, you are touching a dozen of these mouths every week, and you are almost certainly not screening for it, because it is not on your intake form and they are not going to volunteer it.

This is not coming. It is already here, sitting in your operatory, and most of us are still staging and grading these patients with a risk model built for a world that no longer exists.

So I started asking a different question

Once I stopped asking my patients what they were doing wrong — because they were not doing anything wrong — and started asking simply what has changed since I saw you last, I got the same answer over and over and over.

They had started a GLP-1.

Ozempic. Wegovy. Zepbound. Mounjaro. Rybelsus. Their homecare had not changed. Their diet, in most cases, had actually improved. They were not eating more sugar. They were not skipping brushing.

And not one of them — not a single one — had been told that the injection would change the chemistry of their mouth.

Nobody had warned them. Not the prescriber, not the pharmacist, and not us. So they did what any reasonable person does when their teeth start falling apart and no one offers an explanation: they assumed it was their fault.

It is not their fault. And this is the sentence I want you to carry into your next hygiene appointment:

This is not a hygiene failure. It is a chemistry failure.

Those two things look identical across the operatory. They are treated in completely opposite ways. And getting them confused is how we end up shaming a woman who is finally winning.

The reframe: three symptoms, one failure

Here is the shift that reorganized how I assess these patients, and I want you to sit with it for a second because everything downstream depends on it.

We keep trying to sort this patient into a bucket. Is this erosion? Is this caries? Is this periodontal disease?

Stop sorting.

In the GLP-1 mouth, those are not three diagnoses. They are three symptoms of one failure. The mouth has lost its ability to neutralize acid, and it is losing it from several directions at once.

Once you hold that model, the whole picture snaps into focus, and so does the protocol. You are not chasing lesions. You are not chasing pockets. You are rebuilding buffering capacity — the mouth’s ability to defend and repair itself — and every intervention you make should be judged against whether it does that.

Three things are happening simultaneously, and they compound each other.

The saliva goes away. GLP-1 receptor agonists reduce salivary output through several converging routes. Patients eat less, so the glands are stimulated less, and flow follows demand. The drugs also modulate autonomic control of the salivary glands, dampening the parasympathetic signaling that drives watery, protective secretion. And the newest mechanistic work suggests something more direct still — that prolonged, biased activation of the GLP-1 receptor may disrupt the cyclic AMP and calcium signaling that salivary acinar cells depend on to secrete at all, leaving not just less saliva but thicker, stickier saliva that is worse at coating, clearing, and protecting (Biology, 2025). I will flag honestly, here and every time I mention it: this mechanistic layer is early. It is a narrative review synthesizing receptor pharmacology and reported adverse effects, not a randomized trial of salivary flow. Say it that way to your patients and say it that way to your doctor.

The acid comes up. Delayed gastric emptying is not a side effect of this drug class; it is a substantial part of how these medications create satiety. But delayed emptying promotes reflux. In a population-based, active-comparator, new-user cohort of adults with type 2 diabetes drawn from the UK Clinical Practice Research Datalink, patients started on GLP-1 receptor agonists carried roughly a twenty-seven percent higher risk of GERD than patients started on SGLT-2 inhibitors (Annals of Internal Medicine, 2025;178:1268–1278). That is strong human data with an appropriate comparator — not a mouse, not a mechanism. The elevated risk held for every agent in the class except lixisenatide, and GERD complications clustered in ever-smokers and in patients with obesity or pre-existing gastric conditions. Those are the charts that should slow you down. Then layer on the initiation phase, where nausea is among the most commonly reported adverse effects and a subset of patients vomit, most intensely when starting or escalating the dose. Every one of those episodes is a wash of gastric acid across enamel.

And the buffer is broken. This is the one that ties the first two into a knot. Acid challenge is up. Acid defense is down. There is less bicarbonate to neutralize what arrives, so the pH drops further and stays down longer. We can even see this on a test strip: when researchers compared patients with reflux to controls, the GERD group showed measurably lower salivary pH, lower buffering capacity, and lower flow (comparative study, 2021). That is the exact fingerprint of the mouth I have been describing, and in Part 3 I am going to show you how to go looking for it chairside in about ten minutes.

The result is that the same tooth can now erode and decay at the same time, faster than either process would move alone, while the patient’s routine has not changed by a single minute.

What I am not saying

I need to be very clear about something, because this conversation gets twisted online in ways that do real harm to real patients.

This is not an anti-GLP-1 series.

These medications are doing extraordinary things. They are changing metabolic health, cardiovascular risk, and quality of life for people who have fought their own biology for decades and finally have a tool that works. Nobody reading this — and no patient of yours — should stop a prescribed medication because of anything I write. That decision belongs to them and their prescriber, and it is not our lane.

Our lane is the mouth. And here is the good news, which is the entire reason I am writing this series: in the mouth, this is a problem we already know how to solve.

Every single mechanism I just described is a target. Saliva down means we restore moisture and remineralize from the outside. Acid up means we neutralize and protect, especially overnight. Buffer broken means we measure it, rebuild it, and then re-measure so the patient can watch her own number move. Inflammation means we control it now, early, aggressively.

The GLP-1 patient is not a lost cause. She may be the most coachable patient you will ever treat. She is already proving, every single week, that she will commit to a protocol and stick to it. She has the discipline. She just never got the instructions.

That is on us. And it is fixable this week.

Where this series goes

Part 2 is the deep dive, and it is free. It goes underneath the mechanism into what actually happens to the microbiome when the saliva leaves — why less clearance and less buffering create a selection pressure, why the caries species and the periodontal pathogens both win but by completely different routes, and why this patient shows up with new decay and bleeding margins in the same appointment. I wrote it for both sides of the operatory, so it is the piece you can forward straight to a patient without translating a word.

Part 3 is the ten-minute chairside workup, for paid subscribers. The screening script that takes thirty seconds at intake. The objective saliva and buffering test that turns “your mouth seems dry” into a number the patient actually wants to move — which is, in my experience, the single highest-leverage shift available to a hygiene department right now, because it is where case acceptance quietly lives.

Part 4 is the protocol, for paid subscribers. The product-to-deficit map, matched to AAP stage and grade and CAMBRA risk, and the systems work required to make any of it survive contact with a real schedule.

You do not need to wait for the randomized controlled trials to start screening for this. The medication question costs you thirty seconds. The saliva workup takes ten minutes and delegates cleanly to your hygiene team.

These patients are already in your chairs. And they are not failing.

We are missing them.

Let’s stop.

Rooted in science. Based in practicality.

Amber

P.S. Looking for support for your team to have patient-prioritized profit with ease? Let’s set up a time to chart; hit reply or visit www.amberauger.com